ContraFect

$5.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.35 (-6.47%) Today
$0.00 (0.00%) As of 9:47 AM UTC after-hours

Why Robinhood?

You can buy or sell ContraFect and other stocks, options, and ETFs commission-free!

About CFRX

ContraFect Corporation Common Stock, also called ContraFect, is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY. The listed name for CFRX is ContraFect Corporation Common Stock.

CEO
Roger J. Pomerantz
Employees
24
Headquarters
Yonkers, New York
Founded
2008
Market Cap
140.98M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
165.82K
High Today
$5.30
Low Today
$5.05
Open Price
$5.27
Volume
240.43K
52 Week High
$12.10
52 Week Low
$4.45

Collections

CFRX Earnings

-$0.88
-$0.59
-$0.29
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 17, Pre-Market

You May Also Like

GLUU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure